Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial.
DAS28
DMARD
HAQ
PROM’s
Rheumatoid Arthritis
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
28 May 2023
28 May 2023
Historique:
received:
24
04
2023
revised:
15
05
2023
accepted:
26
05
2023
medline:
10
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Several studies have shown that tapering or stopping disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in sustained remission is feasible. However, tapering/stopping bears the risk of decline in physical function as some patients may relapse and face increased disease activity. Here, we analyzed the impact of tapering or stopping DMARD treatment on the physical function of RA patients. The study was a post hoc analysis of physical functional worsening for 282 patients with RA in sustained remission tapering and stopping DMARD treatment in the prospective randomized RETRO study. HAQ and DAS-28 scores were determined in baseline samples of patients continuing DMARD (arm 1), tapering their dose by 50% (arm 2), or stopping after tapering (arm 3). Patients were followed over 1 year, and HAQ and DAS-28 scores were evaluated every 3 months. The effect of treatment reduction strategy on functional worsening was assessed in a recurrent-event Cox regression model with a study-group (control, taper, and taper/stop) as the predictor. Two-hundred and eighty-two patients were analyzed. In 58 patients, functional worsening was observed. The incidences suggest a higher probability of functional worsening in patients tapering and/or stopping DMARDs, which is likely due to higher relapse rates in these individuals. At the end of the study, however, functional worsening was similar among the groups. Point estimates and survival curves show that the decline in functionality according to HAQ after tapering or discontinuation of DMARDs in RA patients with stable remission is associated with recurrence, but not with an overall functional decline.
Identifiants
pubmed: 37297917
pii: jcm12113723
doi: 10.3390/jcm12113723
pmc: PMC10253840
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Joint Bone Spine. 2022 Jan;89(1):105272
pubmed: 34536622
Best Pract Res Clin Rheumatol. 2019 Oct;33(5):101481
pubmed: 32001166
Ann Rheum Dis. 2016 Aug;75(8):1428-37
pubmed: 27261493
Ann Rheum Dis. 2011 Feb;70(2):315-9
pubmed: 21068104
J Rheumatol. 2022 Aug;49(8):867-870
pubmed: 35105710
Ann Rheum Dis. 2016 Sep;75(9):1637-44
pubmed: 26483255
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
J Rheumatol. 2018 Nov;45(11):1515-1521
pubmed: 30173149
Arthritis Rheum. 2009 Aug;60(8):2262-71
pubmed: 19644846
Ann Rheum Dis. 2016 Jan;75(1):45-51
pubmed: 25660991
Rheumatol Ther. 2017 Jun;4(1):1-24
pubmed: 28255897
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Arthritis Res Ther. 2015 Aug 31;17:232
pubmed: 26321751
Arthritis Rheumatol. 2016 Jan;68(1):1-26
pubmed: 26545940
J Rheumatol. 2019 May;46(5):460-466
pubmed: 30504510
Rheumatol Int. 2018 May;38(5):707-714
pubmed: 29626222